Stock listing

NASDAQ:BRVE Braveheart Bio, Inc. Stock

Home listing (NASDAQ) of Braveheart Bio, Inc.

Follow Braveheart Bio, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:BRVE

$20.39 USD +1.86 (+10.0%)

Close on Nov 20, 2026

Past 3 months -31.6% · daily closes, Aug 6, 2026 – Nov 20, 2026, adjusted for splits
Day range
$18.83 – $21.11 USDNov 20, 2026
Volume
866,730 sharesNov 20, 2026
Market cap
$1.84B USDAt the close on Nov 20, 2026 · price × 90.04M shares outstanding
Traded on an average day
$10.60M USDMedian day 342,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:BRVE · Home$20.39 USD+1.86 (+10.0%)866,730$19.29$21.11$18.83$18.53Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BRVE · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$20.39+1.86+10.0%$19.29$21.11$18.83866,730
$18.53-0.25-1.3%$18.48$19.42$17.95706,907
$18.78-0.71-3.6%$19.46$19.46$17.79971,285
$19.49-0.13-0.7%$20.04$20.21$18.71725,376
$19.62-0.88-4.3%$20.41$20.41$19.19536,604
$20.50-0.40-1.9%$20.97$21.30$20.01256,070
$20.90+1.28+6.5%$20.04$21.85$19.41488,966
$19.62+0.16+0.8%$19.13$19.76$18.88211,466
$19.46+0.86+4.6%$19.08$19.87$18.61618,350
$18.60+1.185+6.8%$17.55$18.99$16.89702,051
$17.42-2.69-13.4%$19.84$19.84$16.701,590,097
$20.11-1.285-6.0%$21.54$21.56$19.16655,535
$21.39+0.35+1.7%$20.94$21.53$20.24305,539
$21.04-0.47-2.2%$21.79$21.79$20.51260,119
$21.51+0.32+1.5%$21.29$21.77$20.75533,666
$21.19-0.57-2.6%$21.55$22.20$20.62304,125
$21.76-0.06-0.3%$21.74$21.85$20.77246,219
$21.82-0.05-0.2%$22.00$22.22$21.38156,109
$21.87+0.43+2.0%$21.71$21.96$21.32101,220
$21.44-0.04-0.2%$21.45$21.53$20.58119,555
$21.48+0.44+2.1%$21.14$21.80$20.68156,502
$21.04+0.77+3.8%$20.64$21.36$19.67224,146
$20.27+1.06+5.5%$19.21$20.81$19.15323,870
$19.21+0.50+2.7%$18.72$19.42$18.15333,743
$18.71-0.84-4.3%$19.50$19.59$18.00414,900
$19.55+0.21+1.1%$19.54$20.13$19.18206,100
$19.34+0.01+0.1%$19.33$19.90$18.62462,800
$19.33-1.03-5.1%$20.44$20.56$19.04212,300
$20.36+0.34+1.7%$20.17$20.78$19.22155,100
$20.02+0.93+4.9%$18.91$20.24$18.44255,000
$19.09+0.51+2.7%$18.53$19.32$17.86389,200
$18.58-1.21-6.1%$19.61$19.65$18.47336,900
$19.79-1.56-7.3%$21.59$21.59$19.67590,300
$21.35+0.08+0.4%$21.57$22.02$19.83889,000
$21.27-0.14-0.7%$21.44$21.98$20.77462,800
$21.41+1.21+6.0%$19.90$22.36$19.88669,400
$20.20-2.14-9.6%$22.30$22.30$20.01967,500
$22.34+1.27+6.0%$21.00$22.51$20.37719,200
$21.07+0.45+2.2%$20.25$22.05$20.01389,300
$20.62-2.75-11.8%$23.58$23.86$20.53471,800
$23.37+1.91+8.9%$21.41$23.80$20.70396,700
$21.46-2.15-9.1%$23.21$23.77$21.31521,700
$23.61-1.41-5.6%$25.41$25.41$23.42829,400
$25.02-4.18-14.3%$28.90$28.90$24.631,570,800
$29.20+1.49+5.4%$27.78$29.50$27.472,017,800
$27.71+0.26+0.9%$27.76$28.90$27.16577,400
$27.45+0.74+2.8%$26.82$28.90$26.22550,700
$26.71-0.31-1.1%$26.95$27.98$26.31275,000
$27.02+0.38+1.4%$26.75$27.76$26.29209,200
$26.64-0.61-2.2%$28.12$28.74$26.54283,600
$27.25-1.66-5.7%$28.94$29.50$26.47286,000
$28.91-0.50-1.7%$29.13$29.97$27.93309,700
$29.41+2.67+10.0%$27.18$29.91$27.18613,200
$26.74+0.47+1.8%$25.81$27.48$25.39272,100
$26.27-0.68-2.5%$27.22$27.22$25.19327,600
$26.95+0.67+2.5%$26.53$27.78$25.69394,500
$26.28+0.78+3.1%$25.76$27.06$24.90342,900
$25.50-1.94-7.1%$27.95$27.95$24.31806,200
$27.44-0.42-1.5%$27.98$29.24$27.38162,500
$27.86+0.10+0.4%$27.50$29.00$27.50127,800
$27.76+0.12+0.4%$27.80$28.65$27.01215,200
$27.64+0.14+0.5%$28.29$29.25$27.07155,335
$27.50-0.08-0.3%$27.64$28.00$26.17101,993
$27.58+0.16+0.6%$27.49$28.10$27.12130,500
$27.42-1.55-5.4%$28.43$28.89$26.54176,200
Ticker
NASDAQ:BRVE
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Braveheart Bio, Inc. news

Braveheart Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
10 in the last 12 months · 10 in all · newest Nov 10, 2026 · oldest 2026
Decks
2 decks · latest May 11, 2026

Where Braveheart Bio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BRVE · Home listing · This pageNASDAQUnited StatesUSD
BOATS:BRVEBOATSUnited StatesUSD

Valuation

Price/book 3.7× against a median of 4.9×: 2nd lowest of 9 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.71B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
3.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
Under 6 months of closes

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Braveheart Bio, Inc. · NASDAQ:BRVEUS$1.84BUS$1.71Bn/an/an/a3.7×n/a0.0×n/a
Shanghai Henlius Biotech, Inc. Class H · HKEX:2696US$1.91BUS$2.36B14.7×2.1×12.3×2.8×11.7%0.9×n/a
Trevi Therapeutics, Inc. · NASDAQ:TRVIUS$1.90BUS$1.60Bn/an/an/a6.3×n/a0.0×1.22
Biohaven Ltd. · NYSE:BHVNUS$1.87BUS$1.71Bn/an/an/an/an/an/a1.19
BioCryst Pharmaceuticals, Inc. · NASDAQ:BCRXUS$1.86BUS$1.88Bn/a1.9×n/an/a−37.4%n/a0.62
Immunome, Inc. · NASDAQ:IMNMUS$1.85BUS$1.40Bn/an/an/a4.1×n/a0.0×1.49
Zymeworks Inc. · NASDAQ:ZYMEUS$1.84BUS$2.08B42.5×7.8×40.6×7.1×16.3%1.3×0.69
Vera Therapeutics, Inc. · NASDAQ:VERAUS$1.84BUS$1.53Bn/a149×n/a5.5×n/a0.2×1.13
Hemab Therapeutics Holdings, Inc. · NASDAQ:COAGUS$1.84BUS$1.41Bn/an/an/a4.3×n/a0.0×0.61
Septerna, Inc. · NASDAQ:SEPNUS$1.84BUS$1.38Bn/a14.3×n/a4.3×−61.3%0.1×0.95
Replimune Group, Inc. · NASDAQ:REPLUS$1.81BUS$1.60Bn/an/an/a8.8×n/a0.5×0.78
Median of the othersUS$1.85BUS$1.60B28.6×7.8×26.5×4.9×−12.9%0.1×0.95

Forecasts

5 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
45.25 USD · Analysts' mean
EPS, year to Dec 2026
-1.82 · 5 analysts

Team and board

Officers

OfficerRole
Travis MurdochChief Executive Officer and Board Director
Paul RickeyChief Financial Officer
Brittany de TempleSenior Vice President, Development Operations
Carlos L. del RioSenior Vice President, Cardiovascular Research & Translational Science
Vance RussellSenior Vice President, Chemistry, Manufacturing & Controls (CMC)
Emil deGomaChief Medical Officer
Marc EvanchikChief Scientific Officer
Michele AndersonChief Development Officer
Tyler ChavezChief Business Officer

Board

DirectorRole
Chris ViehbacherChair of the Board

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026+7.4%
Q2 2026Sep 8, 2026 · After close−1.7%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (May 2026)Technical16 slidesMay 11, 2026
Technical PresentationTechnical15 slides

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$439.9M in the latest tranche · US$18 a share · Goldman Sachs & Co. LLC +4
Dealers: Goldman Sachs & Co. LLC (co-lead), Jefferies (co-lead), TD Cowen (co-lead), Stifel (co-lead), Cantor (co-lead)
Sep 8, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on Aug 5, 2026.

Price
US$18.00 a share
Shares offered
21,250,000 shares of common stock
Offering size
US$382.5 million
Underwriters' option
Up to 3,187,500 more shares
Listing
BRVE on the Nasdaq Global Market
Underwriters
Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, Cantor · In the order on the cover
Shares delivered
On or about Aug 7, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceApr 29, 2026
Filed publiclyJul 15, 2026
Amended onceJul 30, 2026
Shares registered with an exchangeAug 3, 2026
Declared effective by the SECAug 5, 2026
Final prospectus, with the priceAug 6, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Aug 6, 2026

Financials

Annual, in USD

Income statement

LineFY2025
Revenue0
Research and development1.49M
Selling, general and administrative3.02M
Operating income-4.50M
Income before tax-66.1M
Net income-66.1M
Earnings per share, basic-0.90

Balance sheet

LineFY2025
Cash and equivalents89.2M
Current assets89.3M
Total assets89.3M
Accounts payable1.06M
Current liabilities5.24M
Total liabilities155.2M
Shareholders' equity-65.9M
Shares outstanding73.2M

Cash flow

LineFY2025
Cash from operations-2.01M
Capital spending-33.6M
Free cash flow-35.6M
Cash from financing124.7M
Change in cash89.2M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 9, 2026Big-stake noticeSEC
8-K · Current reportNov 6, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeNov 5, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 10, 2026Big-stake noticeSEC
10-Q · Quarterly reportSep 8, 2026Quarterly reportSEC
8-K · Current reportSep 8, 2026ResultsSEC
All 53 filings
FilingDateTypeFiled with
SCHEDULE 13D · Big-stake noticeAug 18, 2026Big-stake noticeSEC
3 · Initial statement of ownershipAug 14, 2026Insider tradeSEC
SCHEDULE 13D · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
8-K · Current reportAug 7, 2026Current reportSEC
S-8 · Registration statement for employee plansAug 6, 2026Offer documentSEC
424B4 · ProspectusAug 6, 2026Offer documentSEC
CERT · Exchange's certificate of listingAug 6, 2026Other filingsSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 6, 2026Other filingsSEC
3 · Initial statement of ownershipAug 5, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 5, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 5, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 5, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 5, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 5, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 5, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 5, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 5, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 5, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 5, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 5, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 5, 2026Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringAug 5, 2026Offer documentSEC
8-A12B · Registration of shares for listing on an exchangeAug 3, 2026Other filingsSEC
S-1/A · Registration statement, amendedJul 30, 2026Offer documentSEC
S-1 · Registration statementJul 14, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedJun 8, 2026Offer documentSEC
DRS · Draft registration statementApr 29, 2026Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Braveheart Bio, Inc.’s releases · as of Sep 8, 2026

Common shares
90,038,969
Fully diluted
90,038,969

Fully diluted

LineSharesAs of
Common shares90,038,969Sep 3, 2026

Share count over time

CountShares
Sep 3, 202690,038,969

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Fcpm III Services B.V.21.8M24.2%US$441MSep 30, 2026
Orbimed Advisors LLC12.2M13.5%US$246MSep 30, 2026
a16z Capital Management, L.L.C.10.2M11.4%US$207MSep 30, 2026
Fidelity7.59M8.4%US$153MSep 30, 2026
Frazier Life Sciences Management, L.P.5.27M5.9%US$106MSep 30, 2026
Enavate Sciences Gp, LLC3.67M4.1%US$74.2MSep 30, 2026
Capital Group2.33M2.6%US$47.1MSep 30, 2026
Avoro Capital Advisors LLC1.25M1.4%US$25.4MSep 30, 2026
Vanguard1.15M1.3%US$23.2MSep 30, 2026
BlackRock1.01M1.1%US$20.3MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Eventide Asset Management, LLC910K1.0%US$18.4MSep 30, 2026
Ra Capital Management, L.P.565K0.63%US$11.4MSep 30, 2026
Woodline Partners LP503K0.56%US$10.2MSep 30, 2026
Sun Life465K0.52%US$9.4MSep 30, 2026
Nextech Invest Ltd.417K0.46%US$8.42MSep 30, 2026
EcoR1 Capital, LLC417K0.46%US$8.42MSep 30, 2026
Casdin Capital, LLC400K0.44%US$8.08MSep 30, 2026
Pivotal bioVenture Partners Investment Advisor LLC317K0.35%US$6.41MSep 30, 2026
T. Rowe Price310K0.34%US$6.26MSep 30, 2026
Geode Capital289K0.32%US$5.84MSep 30, 2026
Farallon Capital Management, L.L.C.278K0.31%US$5.61MSep 30, 2026
UBS229K0.25%US$4.63MSep 30, 2026
Schwab146K0.16%US$2.96MSep 30, 2026
Sectoral Asset Management Inc120K0.13%US$2.42MSep 30, 2026
Millennium115K0.13%US$2.32MSep 30, 2026
Perceptive Advisors LLC115K0.13%US$2.32MSep 30, 2026
Seven Grand Managers, LLC113K0.12%US$2.27MSep 30, 2026
Bank of America109K0.12%US$2.19MSep 30, 2026
Integral Health Asset Management, LLC100K0.11%US$2.02MSep 30, 2026
Nan Fung Group Holdings Ltd81,3760.09%US$1.64MSep 30, 2026
Moore Capital Management, LP78,7150.09%US$1.59MSep 30, 2026
Driehaus Capital Management LLC77,5000.09%US$1.57MSep 30, 2026
Cormorant Asset Management, LP70,0000.08%US$1.41MSep 30, 2026
Ameriprise67,2030.07%US$1.36MSep 30, 2026
Rock Springs Capital Management LP60,8370.07%US$1.23MSep 30, 2026
Alyeska Investment Group, L.P.52,0000.06%US$1.05MSep 30, 2026
Citadel51,6000.06%US$1.04MSep 30, 2026
Northern Trust50,6330.06%US$1.02MSep 30, 2026
Cinctive Capital Management LP44,5520.05%US$900KSep 30, 2026
Goldman Sachs41,6450.05%US$841KSep 30, 2026
Squarepoint Ops LLC40,2820.04%US$814KSep 30, 2026
Leonard Rickey Investment Advisors P.L.L.C.36,1090.04%US$729KSep 30, 2026
State Street35,8960.04%US$725KSep 30, 2026
Schonfeld Strategic Advisors LLC27,8560.03%US$563KSep 30, 2026
Marshall Wace, LLP27,0190.03%US$546KSep 30, 2026
Jump Financial, LLC23,8220.03%US$481KSep 30, 2026
ExodusPoint Capital Management, LP21,2450.02%US$429KSep 30, 2026
Burkehill Global Management, LP20,0000.02%US$404KSep 30, 2026
Ghisallo Capital Management LLC20,0000.02%US$404KSep 30, 2026
WINTON GROUP Ltd19,8000.02%US$400KSep 30, 2026

This page holds 50 of 60 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
OrbiMed Genesis GP LLC
Director, 10% owner
Buy1,666,667USD 18.00US$30MAug 7, 2026
OrbiMed Genesis GP LLC
Director, 10% owner
Buy273,333USD 18.00US$4.92MAug 7, 2026
Chimovits Erez
Director, 10% owner
Buy1,666,667USD 18.00US$30MAug 7, 2026
Chimovits Erez
Director, 10% owner
Buy273,333USD 18.00US$4.92MAug 7, 2026
Andreessen Marc L
10% owner
Buy1,100,000USD 18.00US$19.8MAug 7, 2026
Forbion Growth Opportunities Fund III Cooperatief U.A.
10% owner
Buy1,920,000USD 18.00US$34.6MAug 7, 2026
Forbion Growth Opportunities Fund III Cooperatief U.A.
10% owner
Buy1,680,000USD 18.00US$30.2MAug 7, 2026
Lubner David Charles
Director
Buy55,555USD 18.00US$1000KAug 7, 2026
Travis Murdoch
Director, Officer: CEO and President
Buy83,333USD 18.00US$1.5MAug 7, 2026
Anderson Michele A.
Officer: Chief Development Officer
Buy1,111USD 18.00US$19,998Aug 7, 2026
All 13 trades
TradeTradeSharesPriceValueDate
Malek David I
Director
Buy4,166USD 18.00US$74,988Aug 7, 2026
Viehbacher Christopher
Director
Buy83,333USD 18.00US$1.5MAug 7, 2026
Rickey James Paul
Officer: Chief Financial Officer
Buy27,777USD 18.00US$500KAug 7, 2026

Big stakes

StakeStakeSharesDateFiling
Orbimed Advisors LLC13.50%12.2MSep 8, 2026Schedule 13D
Forbion Growth Opportunities Fund III Cooperatief U.A.12.90%11.6MSep 30, 2026Schedule 13G
AH Bio Fund IV, L.P.11.40%10.2MAug 7, 2026Schedule 13D
Travis Murdoch9.30%8.38MSep 30, 2026Schedule 13G
Jiangsu Hengrui Pharmaceuticals Co., Ltd.8.20%7.42MSep 30, 2026Schedule 13G
FMR LLC8.20%7.37MSep 30, 2026Schedule 13G
Frazier Life Sciences Public Fund, L.P.5.50%4.98MAug 7, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Christopher A. Viehbacher
Other companies: Biogen Inc. (President and Chief Executive Officer · Since at least Nov 14, 2022); Axcella Health Inc (Director · May 8, 2019 – May 8, 2019 · Past)
Director · Since at least Aug 5, 2026
James Paul Rickey
Other companies: Alpine Immune Sciences Inc (See Remarks · Jul 24, 2017 – May 20, 2024 · Past); Immune Design Corp (VP, Finance and Administration · Jul 23, 2014 – Jan 7, 2015 · Past)
Chief Financial Officer · Since at least Aug 5, 2026
Jason Coloma
Other companies: Maze Therapeutics, Inc. (Chief Executive Officer · Since at least Jan 30, 2025); Corvus Pharmaceuticals, Inc. (SVP, Chief Business Officer · Jun 8, 2016 – Jun 8, 2016 · Past)
Director · Since at least Aug 5, 2026
Erez Chimovits
Other companies: ADARx Pharmaceuticals, Inc. (Director · Since at least Sep 28, 2026)
Director · Since at least Aug 7, 2026
Jasper Bos
Other companies: enGene Therapeutics Inc. (Director · Since at least Oct 31, 2023)
Director · Since at least Aug 5, 2026
Travis Murdoch
Other companies: Zymergen Inc (Director · Apr 21, 2021 – Oct 19, 2022 · Past)
CEO and President, Director · Since at least Aug 5, 2026
Vineeta Agarwala
Other companies: Tenet Healthcare Corporation (Director · Since at least Dec 11, 2023)
Director · Since at least Aug 7, 2026
Brittany de TempleSenior Vice President, Development Operations · Since at least Nov 4, 2026
Carlos L. del RioSenior Vice President, Cardiovascular Research & Translational Science · Since at least Oct 30, 2026
Chris ViehbacherChair of the Board · Since at least Aug 7, 2026
All 17 people
PersonSeat
David I MalekDirector · Since at least Aug 5, 2026
Emil deGomaChief Medical Officer · Since at least Nov 4, 2026
Marc EvanchikChief Scientific Officer · Since at least Nov 4, 2026
Michele AndersonChief Development Officer · Since at least Aug 5, 2026
Paul RickeyChief Financial Officer · Since at least Nov 4, 2026
Tyler ChavezChief Business Officer · Since at least Nov 4, 2026
Vance RussellSenior Vice President, Chemistry, Manufacturing & Controls (CMC) · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Braveheart Bio, Inc.